

# Curevac N.V.

**55.62** Eur  
+0.42%

ISIN: NL0015436031  
Ticker: 5CV

Sector: Technology services  
Stock exchange: XETRA

Market capitalization: 9.9 billion

**Key Metrics:**

Performance YTD: 20.21%  
Estimated 2020 P/E: -

Earning per share: -137  
Price to book: -

Net Debt: 56 M  
Return on Equity: -

## Fundamental analysis summary

New to the public market and active in biotech, CureVac is one of the competitors in the COVID-19 vaccine race (mainly from Moderna, which wants to create a mRNA-based vaccine). One of its main investors is SAP co-founder Dietmar Hopp and the German government.

## Technical analysis summary

Launched at \$36 at its IPO, it is now at \$66. It was propelled by an announcement of discussions with the European agency to distribute the vaccines. There isn't much substance to analyze and at this stage, it's the far west.

Chart - Year To-Date

